Gonadorelin dosage and evidence

What is Gonadorelin?

How does Gonadorelin work?

Given in pulses, it makes the pituitary gland release LH and FSH, just like the body's own GnRH. Given nonstop, it wears the gland out and shuts that release down instead.

What have studies in people found about Gonadorelin?

Gonadorelin has a solid record in people for one job. It restarts puberty, sex hormones and sperm in people whose brain does not make its own version of this hormone. In those studies it came from a small pump that gave a pulse every one to two hours. It has no tested record at all for what it is mostly sold for now: keeping the testicles working in men on testosterone.

• Men missing the hormone signal, 2002, 76 men on the pump for 12 to 24 months at 5 to 25 ng/kg per pulse: the pituitary signal (LH) came back to normal in 97 percent and testosterone in 93 percent. Men who had gone through some puberty before did well. 92 percent reached normal testicle size, most reached normal hormone levels, and all of them had sperm. The 52 men who never had any puberty did worse. After two years their testicles were still small, sperm counts levelled off at a typical 3 million per mL, and 18 percent still had no sperm. Undescended testicles as a child, seen in 40 percent of that group, predicted the worse result.
• Pump against hormone shots, 2019, 28 men born with the missing signal and no sperm: 10 wore the pump and 18 got the usual hormone shots (hCG and hMG), and they were followed for two years. Chance did not decide who got what. Sperm first showed up at about 6 months on the pump against 14 months on shots. In the end, 90 percent on the pump and 83.3 percent on shots made sperm, a gap too small to count. Testicle size and penis length grew about the same in both groups. Red, hardened skin where the pump needle went in was a common problem.
• Men missing the hormone signal, 1982, a small pump study: hormone signals were back to normal within a week. Testosterone rose from 77 to 520 ng/dL in a month, and three of six men began making sperm.
• Men on testosterone, the use it is mostly sold for: a 2026 review found that direct proof of sperm or fertility coming back after testosterone shuts it down is still thin. How long it works, how safe it is, what schedule to use and who should get it are all still open. No fair test of gonadorelin for this use, with men put into groups by chance, was found.

What this does not tell you: Every study above used a pump that gave a small pulse every 60 to 120 minutes, in people whose own brain signal was missing. The shot that men on testosterone get two or three times a week is a different schedule, a different device and a different group of people, and no study links the two. Nobody has measured what an occasional shot does when outside testosterone is shutting the system down, rather than when it never worked. No study compares gonadorelin with hCG, with clomiphene, or with doing nothing, on testicle size, testosterone inside the testicle, sperm count or time to pregnancy. The pituitary responds to pulses at the right spacing, and the only spacing proven in people is the pump's. No other schedule has been tested to see whether it switches the system on or wears it out.

What do people who took Gonadorelin report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• Discussed almost entirely as a substitute for HCG on testosterone replacement rather than on its own terms, and the verdict from the more experienced posters is that it is a poor substitute.
• The problem people return to is the short half life. Schedules described range from a single weekly injection, which others in the same threads argue cannot do anything, to several small injections a day, and the multi-injection approach is described as a requirement rather than a preference.
• Doses described vary enormously, from tens of micrograms several times daily up to milligram amounts twice a week. The spread itself is treated in the threads as evidence that nothing has been settled.
• One specific objection recurs. Testosterone therapy raises estrogen, and that estrogen dulls the gland at the base of the brain that this drug is meant to wake up. So pulses of it do little unless something else changes. That is why it is usually described alongside an estrogen blocking pill such as enclomiphene rather than alone.
• Comparisons with HCG are unfavourable and blunt, with people describing a far smaller rise in the two hormones that tell the testicles to work, for many more shots and more money. Some do report normal testicle size and normal levels of those hormones using it together with enclomiphene, and others report no perceptible difference in how they felt on either.
• Whether it can be compounded at all is a live regulatory question in these threads, and it is part of why the topic exists rather than a footnote to it.

Sources: Gonadorelin and HCG alternative threads on ExcelMale, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.

The state of the research

The evidence, in charts

The studies we cite

• Study in people1982
  Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone

  Given the way the body gives it, in pulses from a pump, gonadorelin restarted puberty in men whose brains were not signalling. Six men with this condition wore a pump delivering small doses under the skin. Their pituitary hormones were normal within a week. Testosterone rose from 77 to 520 units over a month, into the normal range. Three of the six began producing sperm. Everybody got the treatment, so there is nothing to compare against, and six men is a very small group.

  Pulsatile subcutaneous GnRH by pump normalized gonadotropins within a week, raised testosterone from 77 to 520 ng/dL in one month and produced spermatogenesis in three of six hypogonadotropic men.

  PMID 6813732 New England Journal of Medicine
• Study in people2002
  Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism.

  Pulsed gonadorelin brought hormones back in nearly every man, but fertility depended on his history. 76 men missing a hormone signal wore a pump that gave a small dose every one to two hours for up to two years. Testosterone and the pituitary signal came back to normal in almost all. Men who had been through some puberty ended with normal testicle size and sperm. The 52 who never had puberty did not, and about one in five still had no sperm. Undescended testicles in childhood predicted that failure.

  76 men on pulsatile GnRH at 5 to 25 ng/kg per pulse for 12 to 24 months. LH normalized in 97 percent and testosterone in 93 percent. Men with some prior puberty reached normal testis size, FSH, inhibin B and sperm in the ejaculate; the 52 with none did not, ending at 11 plus or minus 0.4 mL testicular volume, a median sperm count of 3 million per mL and 18 percent still azoospermic at 24 months. Prior cryptorchidism and low baseline inhibin B predicted failure.

  PMID 12213860 Journal of Clinical Endocrinology and Metabolism
• Study in people2019
  The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men.

  The pump got sperm going sooner, but no more men got there in the end. 28 men producing no sperm were compared: 10 wore a gonadorelin pump and 18 took the usual hormone injections. Nobody was assigned by chance, so the groups were not built alike. First sperm appeared at about six months on the pump against fourteen on injections. By the end roughly nine in ten succeeded either way, a gap too small to call. Skin redness and hardening at the pump site was common.

  Nonrandomized comparison in 28 azoospermic men: 10 on a pulsatile gonadorelin pump and 18 on cyclical hCG and hMG. Median time to first spermatogenesis 6 against 14 months (p=.01), but the eventual rates, 90 percent against 83.3 percent, differed significantly in neither the superiority nor the non-inferiority test. Allergic skin erythema and scleroma at the infusion site was a common pump side effect. The authors declared no conflicts.

  PMID 30569789 American Journal of Men's Health
• Review of studies2026
  Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review.

  A review of the literature, not a study, and its answer is that the evidence is not there. It surveys kisspeptin, gonadorelin-type and neurokinin approaches to restarting the reproductive axis after testosterone shuts it down. The authors conclude that direct evidence of restored sperm production or fertility after that kind of suppression remains limited. How long it works, whether it is safe, what schedule to use, and who should get it are all unsettled. The authors declare no commercial relationships.

  Reviews kisspeptin, GnRH-related and neurokinin approaches to testosterone-induced suppression of the hypothalamic-pituitary-testicular axis and concludes that direct evidence of restored spermatogenesis or fertility after such suppression remains limited, with long-term efficacy, safety, protocols and patient selection all unresolved. The authors declare no commercial relationships.

  PMID 42666625 Frontiers in Reproductive Health
• Animal study1978
  Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone

  In monkeys with damage to the brain's hormone center, hourly pulses of GnRH brought back LH and FSH. A steady drip did not, and it wore out the pituitary gland.

  In monkeys with hypothalamic lesions, hourly GnRH pulses restored LH and FSH secretion while continuous infusion failed and desensitized the pituitary.

  PMID 100883 Science